NCT07101588View on ClinicalTrials.gov

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

December 30, 2028

Conditions
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
COMBINATION_PRODUCT

Ruxolitinib, Decitabine

"1. Decitabine: 20 mg/m²/day, administered from Day -15 to Day -10.~2. Ruxolitinib:~ * 10 mg twice daily (bid), Day -15 to Day -5~ * 5 mg twice daily (bid), Day -4 to Day -3~ * 5 mg once daily (Qd), Day -2"

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

UNKNOWN

collaborator

Peking University People's Hospital

OTHER

lead

Chinese PLA General Hospital

OTHER